Sanofi, Regeneron to Amend Agreement for Kevzara & Praulent

Sanofi SNY and its collaboration partner, Regeneron Pharmaceuticals REGN intend to restructure their antibody collaboration into a royalty-based agreement for Kevzara (sarilumab) and Praluent (alirocumab). However, the terms of the agreement related to blockbuster drug, Dupixent (also included in the antibody collaboration) will remain unchanged.